Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.
Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Elliott M, Mangaonkar A, Matin A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Yates S, Sneider A, Dworkin E, Patel AA, Bazinet A, Senapati J, Bataller A, DiNardo C, Kadia T, Tefferi A. Gangat N, et al. Among authors: badar t. Am J Hematol. 2025 Feb;100(2):260-271. doi: 10.1002/ajh.27564. Epub 2024 Dec 13. Am J Hematol. 2025. PMID: 39671248 Free PMC article.
Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.
Gangat N, McCullough K, Johnson I, Al-Kali A, Begna KH, Patnaik MM, Litzow MR, Hogan W, Shah M, Alkhateeb H, Mangaonkar A, Foran JM, Badar T, Palmer JM, Sproat L, Arana Yi CY, Pardanani A, Tefferi A. Gangat N, et al. Among authors: badar t. Am J Hematol. 2022 Jun 1;97(6):E214-E216. doi: 10.1002/ajh.26539. Epub 2022 Mar 24. Am J Hematol. 2022. PMID: 35303376 Free article. No abstract available.
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, Abdallah M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Tefferi A. Gangat N, et al. Among authors: badar t. Am J Hematol. 2024 Feb;99(2):193-202. doi: 10.1002/ajh.27138. Epub 2023 Dec 10. Am J Hematol. 2024. PMID: 38071734
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
Karrar O, Abdelmagid M, Rana M, Iftikhar M, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Elliott MA, Mangaonkar A, Saliba A, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Tefferi A, Gangat N. Karrar O, et al. Among authors: badar t. Am J Hematol. 2024 Feb;99(2):E63-E66. doi: 10.1002/ajh.27180. Epub 2023 Dec 15. Am J Hematol. 2024. PMID: 38100217
Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome.
Badar T, Shetty A, Bueso-Ramos C, Cortes J, Konopleva M, Borthakur G, Pierce S, Huang X, Chen HC, Kadia T, Daver N, Dinardo C, O'Brien S, Garcia-Manero G, Kantarjian H, Ravandi F. Badar T, et al. Am J Hematol. 2015 Sep;90(9):769-73. doi: 10.1002/ajh.24074. Epub 2015 Jul 27. Am J Hematol. 2015. PMID: 26017166 Free PMC article. Clinical Trial.
Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms.
Alkhateeb HB, Nanaa A, Viswanatha D, Foran JM, Badar T, Sproat L, He R, Nguyen P, Jevremovic D, Salama ME, Greipp P, Gangat N, Tefferi A, Litzow MR, Mangaonkar AA, Shah MV, Patnaik M, Al-Kali A. Alkhateeb HB, et al. Among authors: badar t. Blood Adv. 2022 Jan 25;6(2):528-532. doi: 10.1182/bloodadvances.2021005738. Blood Adv. 2022. PMID: 34644397 Free PMC article.
Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts.
Farrukh F, Chetram D, Al-Kali A, Foran J, Patnaik M, Badar T, Begna K, Hook C, Hogan W, McCullough KB, Mangaonkar A, He R, Gangat N, Tefferi A. Farrukh F, et al. Among authors: badar t. Am J Hematol. 2022 Jun 1;97(6):E210-E214. doi: 10.1002/ajh.26533. Epub 2022 Mar 29. Am J Hematol. 2022. PMID: 35293000 Free article. No abstract available.
Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting.
Singh A, Al-Kali A, Foran JM, Elliott MA, Begna K, Badar T, Khera N, Fleti F, Abdelmagid M, Reichard KK, Ketterling RP, Pardanani A, Gangat N, Tefferi A. Singh A, et al. Among authors: badar t. Am J Hematol. 2022 Oct;97(10):E377-E379. doi: 10.1002/ajh.26672. Epub 2022 Aug 12. Am J Hematol. 2022. PMID: 35959963 Free article. No abstract available.
Autoimmune manifestations in STAG2-mutated myeloid neoplasms.
Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Foran J, Begna K, Gangat N, Patnaik M, Tefferi A, Litzow M, Mangaonkar A, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Katamesh B, et al. Among authors: badar t. Ann Hematol. 2022 Dec;101(12):2785-2787. doi: 10.1007/s00277-022-04995-5. Epub 2022 Oct 3. Ann Hematol. 2022. PMID: 36184685 No abstract available.
108 results